ClinicalTrials.Veeva

Menu

Effect of Nava on Weaning Outcome in Patients With Mechanical Ventilation

S

Southeast University, China

Status

Completed

Conditions

ARDS

Treatments

Device: PSV
Device: NAVA

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05219643
NAVA2021

Details and patient eligibility

About

This study intends to compare the effects of NAVA and PSV on weaning success rate and mechanical ventilation time in patients with tracheotomy patients through a randomized controlled study.

Full description

For patients with difficult weaning, NAVA can shorten the time of mechanical ventilation, but there is no large-scale study to explore the effect of NAVA on the weaning success rate and mechanical ventilation time of patients with gas resection. Therefore, this study intends to compare the effects of NAVA and PSV on weaning success rate and mechanical ventilation time in patients with tracheotomy patients through a randomized controlled study.

It is a prospective, multicenter, parallel group, single blind, randomized controlled tria。

Enrollment

130 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Tracheotomy and invasive mechanical ventilation is expected to be required for > 48h;
  2. When support pressure ≤ 15 cmH2O, it can withstand pressure support ventilation (PSV) time > 1h;

Exclusion criteria

  1. Age < 18 years or > 85 years;
  2. Deep sedation.
  3. Severe hemodynamic instability (norepinephrine or equivalent converted dose of other vasoactive drugs > 1ug / kg.min or map ≤ 65mmhg)
  4. Severe respiratory center depression, high paraplegia, neuromuscular disease;
  5. Esophageal obstruction, esophageal perforation, severe esophageal variceal bleeding, upper gastrointestinal surgery, diaphragmatic hernia and thoracic deformity;
  6. Patients with chronic respiratory diseases requiring long-term home oxygen therapy;
  7. Patients with severe coagulation dysfunction (INR > 1.5, APTT > 44s, history of leukemia);
  8. Severe other organ dysfunction is expected to die in a short time (7 days) or palliative treatment.
  9. The estimated survival time of advanced solid organ or hematological system tumors is < 30 days
  10. Participate in other clinical studies within 30 days;
  11. Failing to sign the informed consent form;

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

130 participants in 2 patient groups

NAVA
Experimental group
Description:
Received NAVA.
Treatment:
Device: NAVA
PSV
Active Comparator group
Description:
Received PSV.
Treatment:
Device: PSV

Trial contacts and locations

1

Loading...

Central trial contact

Yang Yi, MD; Liu Ling, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems